MetaCap

Ascendis Pharma A/S (ASND)

NASDAQ: ASNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

252.73-3.23 (-1.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ASND stock chart

Technical analysis

Key statistics

All statistics
Market cap
$16.58B
EPS (TTM)
$15.21
52-week range
188.08 – 282.15
Day range
251.55 – 256.50
Volume / Avg
602.89K / 750.65K
Beta
—

52-week range

$188.08$282.15

ASND stock today

Shares of Ascendis Pharma A/S (ASND) finished lower on Nov 20 at $252.73, a drop of 1.26% or $3.23 per share, versus the S&P 500's 3.70% decline. At this level, ASND sits in the middle of its 52-week range of $188.08 to $282.15: 10.4% below the high, set on Jul 9, 2026 and 34.4% above the low. ASND is up 18.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.1%.

At 16.6x trailing earnings, Ascendis Pharma A/S trades below the peer-group median of 31.2x. Its forward P/E of 20.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Ascendis Pharma A/S

Company profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jan Moller Mikkelsen
Headquarters
Hellerup
Employees
1,189
IPO year
2015

Analyst forecast

Forecast

Consensus (21 analysts)

strong_buy

Avg. price target

$315.78+24.95%

  • Strong buy 5
  • Buy 15
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $273.12High $354.86

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$1.24 vs $1.13
Surprise
+9.73%

ASND news

All ASND news

Ascendis Pharma A/S peers

Health Care sector
ASND peer companies
CompanyPrice% ChgMarket capCompare
BBIOBridgeBio Pharma Inc.76.03-2.75%$14.81Bvs ASND
JAZZJazz Pharmaceuticals plc230.26-2.62%$14.78Bvs ASND
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs ASND
ELANElanco Animal Health Incorporated25.74-2.09%$12.87Bvs ASND
RDYDr. Reddy's Laboratories Ltd14.89+0.40%$12.41Bvs ASND
BMRNBioMarin Pharmaceutical Inc.60.41-1.64%$11.70Bvs ASND
VTRSViatris Inc.19.63-1.26%$22.50Bvs ASND
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs ASND

Indexes, lists and sector

Ascendis Pharma A/S stock FAQ

What is Ascendis Pharma A/S's stock price today?

ASND last traded at $252.73 as of Nov 20, 4:00 PM EST, down 1.26% on the day. Prices are delayed at least 15 minutes.

What is ASND's P/E ratio?

ASND trades at a trailing P/E ratio of 16.62 and a forward P/E of 20.47, compared with a median of 31.2 for its closest peers.

Who is Ascendis Pharma A/S's CEO?

Mr. Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S, which has about 1,189 employees.

What is the ASND 52-week high?

The 52-week high for ASND is $282.15 and the 52-week low is $188.08. The stock is currently 10.4% below its high.

Compare ASND